This week, the overall grades of 4 Pharmaceuticals stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

This is a rough week for Revance Therapeutics, Inc. (RVNC). The company’s rating falls to D from the previous week’s C. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of RVNC stock.

Slipping from a C to a D rating, Aralez Pharmaceuticals Inc. (ARLZ) takes a hit this week. The company also gets F’s in operating margin growth, earnings revisions, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ARLZ stock.

Intellipharmaceutics International Inc.’s (IPCI) rating weakens this week, dropping to a F versus last week’s D. Intellipharmaceutics International Inc. develops drug delivery technologies. The company also gets F’s in sales growth and free cash flow. For more information, get Portfolio Grader’s complete analysis of IPCI stock.

Merus Labs International Inc. (MSLI) declines this week from a D to a F. Merus Labs International Inc. acquires and licenses niche branded pharmaceutical products in the United States and Canada. The company also gets F’s in earnings growth, earnings revisions, and earnings surprise. For more information, get Portfolio Grader’s complete analysis of MSLI stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.